Ulixertinib is a novel, reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with high potency and selectivity. It is currently under investigation in clinical trials for a range of tumor types.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 869886-67-9
N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)-4-pyridinyl]-1H-pyrrole-2-carboxamide
KSERXGMCDHOLSS-LJQANCHMSA-N
CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)N[C@H](CO)C3=CC(=CC=C3)Cl)Cl